An observational study in Paroxysmal Nocturnal Hemoglobinuria, Natural History Study, sponsored by CARE Pharma Shanghai Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-05.
Sponsored by CARE Pharma Shanghai Ltd. · Observational
This is a single-center observational study conducted in adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis.
This observational study consists of two parts, one part is retrospective study which aims to collect medical chart data to calculate the mean change or mean incidence rates of LDH, hemoglobin, PNH-related symptoms and PNH-related events over 6 months.
The other part is cross-sectional study to detect the total C5 level in PUMCH at the latest follow-up visit in eligible PNH patients with high-risk hemolysis, to show the difference between eligible PNH patients and healthy people and to explore the related clinical factor influencing high-level total C5 using logistic regression model.
107 studies on the registry are indexed under Hemoglobinuria; 10 are open to participants now.
This study's enrollment of 67 is close to the median of 64 across 16 observational studies indexed under Hemoglobinuria.
Browse Hemoglobinuria studies →CARE Pharma Shanghai Ltd. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with paroxysmal nocturnal hemoglobinuria of high-risk hemolysis in China
Exclusion Criteria:
the mean change of LDH
the mean change of LDH over 6 months
Time frame: 6 months
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CARE Pharma Shanghai Ltd.